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Abstract 
Background: Duodenal adenocarcinoma (DA) is a rare yet aggressive malignancy, with increasing incidence in the 
last decades. Its low frequency has hampered a thorough understanding of the pathogenesis of the disease and of 
its biology, limiting the identification of tailored therapeutic options. A large body of evidence has clearly shown the 
clinical relevance of immune cells in solid tumors, correlating immune features with post-surgical prognosis. The aim 
of this study was to analyze the immune contexture in a cohort of duodenal adenocarcinomas surgically resected at 
our Institution and define its correlation with clinical variables.
Methods: Tissue slides from paraffin-embedded tumor specimens of 15 consecutive DA and 3 adenomas that 
underwent a pancreaticoduodenectomy in our center between 2010 to 2018 were immunohistochemically stained. 
The density (percentage of immune reactive area, IRA%) of immune markers CD45RO, CD8, CD20, IL-17, PD-1, CD68 
was quantified by computer-assisted image analysis. Demographic, clinical, histopathological data were collected.
Results: In our population, median IRA % (IQR) of immune subsets was respectively CD45RO-TILs 2.19 (2.14), CD8-TIL 
0.42 (0.81), CD20-TILs 0.22 (0.51), CD20-TLT 2.84 (4.64), CD68-TAM 2.19 (1.56),  IL17+ cells 0.39 (0.39), PD1-TILs 0.19 (0.41). 
The median follow-up was 47.5 (22.4–63.3) months. At statistical analysis, the density of CD8-TILs inversely correlated 
with lymph node ratio (p = 0.013), number of metastatic lymph nodes (p = 0.019), and was lower in N+ adenocarcino-
mas compared to N0 (1.07 vs 0.29; p = 0.093), albeit not significantly. Stratifying patients for the N status, the density of 
CD8-TILs decreased with the increasing of the N stage (p = 0.065) and was lower in patients who experienced recur-
rence and died for the disease (0.276 vs 0.641; p = 0.044). Notably, also CD68-TAM distribution was different in patients 
who had recurrence versus patients who did not (1.028 vs 2.276; p = 0.036).
Conclusions: Immune cells showed variable expression in correlation with common prognostic factors, suggesting 
T cell infiltration may play a protective role towards lymphatic spread of disease and nodal metastatization. Further-
more, T cell density and macrophage infiltration were associated to a lower risk of recurrence and disease related 
death. A multicentric approach may be indicated to allow analysis of larger cohorts of patients, potentially increasing 
the power of our observations.
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Background
Within small bowel cancers (SBC), adenocarcinomas 
represent the 36.9% of the whole, the majority of them 
originating in the duodenum (49–58%) [1, 2]. Overall, 
duodenal adenocarcinomas (DA) represent less than 1% 
of all gastrointestinal cancers [3], yet they are aggres-
sive malignancies, with increasing incidence in the last 
decades [1, 3, 4]. Surgical resection is the mainstay of 
treatment for local disease, but unfortunately, a large pro-
portion of patients are not eligible, because the lesion is 
either locally advanced or metastatic [1, 3, 5]. In resected 
disease, the 5-year overall survival (OS) is 51.2%; the 
prognosis remains dismal, despite being more favorable 
than for other periampullary adenocarcinomas. Negative 
prognostic factors include presence of nodal and distant 
metastases, positive resection margins, lymphovascular 
and perineural involvement, high tumor (T) stage, large 
extent of nodal disease, and poorly differentiated histol-
ogy, with lymph node metastases and lympn node ratio 
(LNR) having the highest prognostic yield [1, 5, 6].
The low frequency of duodenal cancers has hampered 
a refined characterization and a thorough understanding 
of the pathogenesis of the disease, since the few available 
studies, performed on mono-centric case series, often 
include patient cohorts spanning across several years and 
include both resected and unresectable lesions [7, 8]. The 
larger studies available either grouped duodenal adeno-
carcinoma with periampullary malignancies or with 
small bowel tumors, not being able to discriminate the 
peculiar features of DA [2, 9, 10]. Availability of limited 
information regarding the optimal surgical approach, the 
type and schedule of chemotherapy, the possibility to use 
immunotherapy has so far prevented from improvement 
in the clinical management of duodenal cancer patients. 
Moreover, patients with lesions at different stages are 
often grouped together, possibly hiding subgroups of 
patients who could benefit from adjuvant chemotherapy.
In consideration of these findings and of the failure 
to appropriately stratify patient prognosis with the cur-
rently available prognostic markers, the possibility to 
use immune-related characteristics as an additional 
factor in prognostic stratification algorithms has been 
recently investigated [11]. The tumor microenviron-
ment (TME) is characterized by a variably large and 
heterogenous immune infiltrate, which has been vari-
ably associated to patient outcome across multiple can-
cer types [12, 13]. Critical features to be considered are 
the abundance of different populations, their localiza-
tion in the core or at the invasive margin of the tumor 
and their spatial organization. Human colo-rectal can-
cer (CRC) has served as a prototype for studies aimed at 
assessing the clinical relevance of immune cells [14–17]. 
Based on this, an “immunoscore” inclusive of evaluation 
of CD3+ and CD8+ T cells infiltration at the tumor Core 
and invasive margin has been shown to reliably predict 
prognosis in CRC [18], and has been further validated 
in a multicenter study [19]. However, despite the close 
anatomic and histopathological similarities between the 
colonic and duodenal tissues, no studies have assessed 
the clinical relevance of immune cells in duodenal can-
cer. The lack of consensus on the clinical management 
and postsurgical therapeutic approaches for DA patients 
would benefit from the identification of variables contrib-
uting to better patient stratification.
Methods
Patients and study design
The cohort study included 18 patients aged older than 
18 with histologically proven duodenal adenocarcinoma 
or adenoma, consecutively resected at the Humani-
tas Clinical and Research Center-IRCCS between 2010 
and 2018. Histological diagnosis of ampullary neo-
plasm was an exclusion criterium. All patients included 
in the study had undergone either a pylorus-preserving 
pancreaticoduodenectomy by Longmire-Traverso or 
a Whipple procedure, according to the location of the 
lesion. Clinical features of the cohort are summarized 
in Table 1. Patients’ demographics, clinical, surgical and 
histopathological data were prospectively collected for 
following analyses and were retrospectively analyzed. 
Written informed consent was obtained from each 
patient included in the study. The study protocol was in 
accordance with the ethical guidelines established in the 
1975 Declaration of Helsinki and compliant to the pro-
cedures of the local ethical committee of the institution. 
Tumors were staged according to TNM (Tumor-Nodes-
Metastasis) staging system 8th ed. Investigators who per-
formed the assessment of immune variables were blinded 
to the clinical data. The preoperative workup consisted 
of a variable combination of contrast-enhanced CT, 
EGDS, EUS, FNAB with histopathological examination. 
Clinical evaluation, biochemical analysis comprehensive 
of tumor markers, and whole-body CT scan, were car-
ried out every 4  months, for the first 2  years and then 
every 6  months, according to the follow-up protocol of 
our institute. Time and location of recurrence, time and 
cause of death, and survival state were recorded for each 
patient.
Keywords: Duodenal cancer, Tumor infiltrating cells, Prognosis
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Immunohistochemistry
2  μm-thick consecutive tissue sections were prepared 
from formalin-fixed and paraffin-embedded tissues, 
provided by the Pathology Department of the Humanitas 
Clinical and Research Center, and processed for immu-
nohistochemistry. Briefly, after deparaffinization and 
rehydration, antigen retrieval was performed by heat 
treatment using EDTA buffer (0.25  mM, pH8, Dako) or 
citrate buffer (0.01 M, pH6, SIGMA-ALDRICH) in water 
bath at 98 °C for 20 min or pressure cooker. Endogenous 
peroxidases were blocked by incubation with 3%  H2O2 
for 15 min at room temperature, followed by incubation 
for 30  min with 2% BSA to block non-specific binding. 
The sections were then incubated with primary antibod-
ies anti-human CD68 (Dako, KP-1 clone, diluted 1:1000), 
CD20 (Dako, L26 clone, diluted 1:200), CD8 (Dako, 
C8/144B clone, diluted 1:100), PD-1 (Abcam, NAT105 
clone, diluted 1:50), CD45RO (Dako, UCHL1 clone, 
diluted 1:200), IL-17 (R&D, AF-317-NA, 1:500) for 1  h 
at room temperature, followed by incubation with the 
detection system MACH 1 (Biocare Medical) or Anti-
Goat Polymer kit (Biocare Medical). Diaminobenzidine 
tetrahydrochloride (Biocare Medical) was used as chro-
mogen. Nuclei were lightly counterstained with a freshly 
made hematoxylin solution (Dako). The sections were 
then washed in water, mounted and analysed under an 
optical microscopy.
Image analysis
To obtain the density of immune cells, tissue slides were 
digitized after staining procedure, using a computer-
aided slide scanner (Olympus VS120 DotSlide). An 
expert pathologist blinded to clinical data selected three 
non-contiguous, non-overlapping microscopic areas 
of stained slides in the invasive margin (IM) area, com-
prising approximately 50% of tumor and 50% of stromal 
tissue. For CD20-TLT analysis, 3 non-contiguous fields 
were chosen representing the entire CD20 positive area 
within the TLT, regardless of the location in the tumor or 
in the stroma. Both sampled microscopic area and light 
density were maintained fixed throughout the analy-
sis. An image analysis software (Image Pro Premiere) 
was used to automatically determine the percentage of 
immune reactive area (IRA%) of the digitized images. 
The mean value, obtained from the three different micro-
scopic areas, was calculated for each patient and used for 
subsequent analyses.
Statistical analysis
Statistical computations were performed using the soft-
ware IBM-SPSS (Chicago, USA), STATA 14.0 (StataCorp. 
2015. College Station, TX) and the software GraphPad 
Prism 7 (GraphPad Software Inc., San Diego, USA). For 
image analyses, for each patient the mean value was cal-
culated from three images. Correlation between IRA% 
Table 1 Demographic and  clinico-pathological 
characteristics of  included patients and  pathological 
tumor characteristics
Only adenocarcinoma patients have been included. a n (%); b median (IQR)
Patients and tumor characteristics
Variable Adenocarcinomas 
(n = 15)
Sexa
 Female 3 (20%)
 Male 12 (80%)
Age at  operationb 73 (65–78)
Clavien-Dindo ≥ IIIba 5 (33%)
Post-operative  mortalitya 3 (20%)
DA on  adenomaa 3 (20%)
Portion of duodenum  involveda
 I 1 (7%)
 II 13 (86%)
 III 1 (7%)
 IV 0 (0%)
TNM staging 7th edition
 Ta
1–2 2 (13%)
3–4 13 (87%)
Na
 0 7 (47%)
 1 2 (13%)
 2 6 (40%)
Stage grouping 7th  editiona
 I 2 (13%)
 II 5 (34%)
 III 8 (53%)
Histological grade (G)a
 1–2 7 (46%)
 3–4 8 (54%)
Resection status (R)a
 0, n (%) 14 (93%)
 1, n (%) 1 (7%)
 2, n (%) 0 (0%)
n° of retrieved lymph  nodesb 23 (14–28)
n° of positive lymph  nodesb 2 (0–3)
Lymph node  ratiob 0.689 (0–0.115)
Perineural  invasiona 5 (33%)
Lymphovascular  invasiona 5 (33%)
Adjuvant  chemotherapya 6 (40%)
Adjuvant  radiotherapya 0 (0%)
Disease  recurrencea 3 (20%)
Disease related  deatha 3 (20%)
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values of immune cells were estimated by nonparamet-
ric Spearman Rank correlation coefficient test and lin-
ear regression analysis. Differences between immune 
variables in groups was estimated by non-parametric 
Mann–Whitney test. Kruskal–Wallis test was used to 
assess differences in median expression between more 
than two groups. For each test, only two-sided P values 
lower than 0.05 were considered statistically significant. 
The categorical variables were reported as a number and 
percentage, while continuous variables were reported as 
the median and interquartile range (IQR). Only patients 
with complete data were considered.
Results
Patient and tumor characteristics are listed in Table  1. 
The cohort included 15 duodenal cancers (DA) and 3 
duodenal adenomas (Ad), from patients consecutively 
resected from 2010 to 2018 in our institution. Three 
among the adenocarcinomas progressed from an initial 
duodenal adenoma (DA on Ad). Histopathological evalu-
ation of duodenal cancer specimens revealed an indeter-
minate histotype (Not Otherwise Specified, NOS) in the 
majority of cases, a mucinous component in 5 cases, one 
intestinal histotype and one adenosquamous. Most of the 
lesions were well circumscribed, often with a polypoid 
nature. An invasive front, where tumor cells intermin-
gled with healthy tissue, was recognizable (Fig. 1a). The 
depth of invasion varied from perforation of the lamina 
propria to involvement of adjacent organs. The three 
adenoma specimens presented features similar to colon 
polyps, with delimitated borders and a clear base of 
implant, and had various grades of dysplasia from low to 
high. The median follow-up was 47.5 (22.4–63.3) months. 
At the time of analysis, we recorded 3 events of recur-
rence, respectively at 2.8  months, 4 and 17.8  months 
after surgery. Estimated Recurrence Free Survival (RFS) 
with (95% CI) was 74.2 months (56.4–92.0). The sites of 
recurrence were liver (1 patient), regional lymph nodes 
(1 patient) and combination of liver and interaortocaval 
lymph nodes (1 patient). All the three patients who 
relapsed experienced a disease related death respectively 
at 10.6  months, 12 and 33.8  months after surgery. Esti-
mated disease-specific survival (DSS) with (95%CI) was 
73.9 months (56.4-92.0).
Immune cells infiltrating duodenal cancer specimens
By immunohistochemistry, we analyzed the infiltra-
tion of CD8+ , CD45RO+ , PD-1+ T cells (from now 
on referred to as tumor-infiltrating T cells, TILs), 
IL-17+ cells, CD20+ B cells and CD68+ tumor-associ-
ated macrophages (TAM) (Fig. 1b–h). Because CD20+ B 
cells localized not only as interspersed cells (Fig. 1f ) but 
also as dense aggregates (Fig. 1g), we analyzed these two 
immune compartments as distinct, namely CD20-TILs 
and CD20-TLT [20]. In general, for all the immune types 
considered, immune cells localized both in the tumor 
core (TC) and at the invasive margin (IM). Notably, a 
considerable number of immune cells was also present in 
Fig. 1 Immunohistochemical evaluation of immune cells in human duodenal cancer. a Representative picture of a human duodenal 
adenocarcinoma specimen; the invasive front (orange arrow) and tumor core regions (black arrow) are indicated. b–h Representative pictures of 
CD45RO-TILs (b), CD8-TILs (c), IL17+ cells (d), PD1-TILs (e), CD20-TILs (f), CD68-TAM (h) at the invasive margin and CD20-TLT (g) in the tumor stroma. 
Scale bars = 500 μm (a), 200 μm (b–h). TILs: tumor-infiltrating lymphocytes; TLT: tertiary lymphoid tissue; TAM: tumor-associated macrophages
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the mucosa of the peritumor healthy tissue, in particular 
CD8-TILs and CD68+ macrophages (Fig.  1c, h). Quan-
titative assessment by computer-assisted image analysis 
of immune cell densities (immunoreactive area (IRA%)) 
at the invasive margin of adenocarcinoma specimens 
revealed heterogenous distribution of the different cell 
types across patients, with median IRA% (IQR) respec-
tively CD45RO-TILs 2.19 (2.14), CD8-TIL 0.42 (0.81), 
CD20-TILs 0.22 (0.51), CD20-TLT 2.84 (4.64), CD68-
TAM 2.19 (1.56), IL17+ cells 0.39 (0.39), PD1-TILs 0.19 
(0.41) (Fig.  2a). With the exclusion of CD20-TLT, for 
which we specifically analyzed those areas where they 
were localized (Fig. 1g), the most frequent immune type 
was by far CD45RO-TILs, closely followed by CD68-
TAM, with a maximum value of 4.7 and 5.3 respectively.
As in other tumor types, B cells were preferentially 
located in tertiary lymphoid tissue (CD20-TLT) rather 
than interspersed (CD20-TILs), confirming previous 
findings [20]. Spearman correlation analysis showed 
a significant correlation among CD45RO-TILs and 
IL17+ cells (p = 0.007; r = 0.61) (Fig.  2b), whereas CD8-
TILs correlated with PD1 TILs (p = 0.023; r = 0.53) 
(Fig.  2c). In contrast, CD20+ B cells correlated only 
among themselves (TLT and TILs) (p = 0.013, not 
shown), suggesting that they could represent an immune 
compartment distinct from the others analyzed. For the 
two lymphoid immune populations most relevant in 
prognostic studies performed in CRC, CD45RO-TILs 
and CD8-TILs, we analyzed whether there was a prefer-
ential localization at the invasive margin (IM) or tumor 
core (TC) and we found very similar values (Fig. 2d) and 
a significant concordance of the distribution in the two 
compartments (p = 0.002 and p = 0.004) (Fig. 2e, f ).
Variation of immune cell infiltration along the process 
of tumorigenesis and according to histotypes
To test whether immune cell infiltration varies accord-
ing to evolution of disease, we compared the density of 
immune cells in adenomas, adenocarcinomas and ade-
nocarcinomas progressed from adenomas. Surprisingly, 
the distribution of immune cells in the three groups was 
quite homogeneous for all the immune variables consid-
ered (Fig.  3a), thus not evidencing a marked modifica-
tion of immune infiltrate in malignant lesions compared 
to benign ones. Considering the histotype, CD20-TLT 
infiltrate was significantly lower in DA with a mucinous 
histotype compared to the NOS DA (median:1.173 vs 
median:5.437; p = 0.01 by Mann–Whitney) (Fig.  3b). 
Moreover, we overall observed a less abundant B and T 
lymphocyte infiltration in mucinous DA compared to 
NOS DA, even if not statistically significant, possibly 
because of the heterogeneity and scarce numerosity.
Correlation of immune cells with prognostic factors 
and recurrence
Then, we tested the relationship of immune cell 
infiltration with well-known clinical and pathologi-
cal variables, commonly used as prognostic factors. 
At Spearman correlation analysis, we found a sig-
nificant inverse correlation between infiltration of 
CD8-TILs and lymphnode ratio (LNR) (p = 0.013) 
and between density of CD8-TILs and number of 
metastatic lymphnodes (p = 0.019) (Table  2). Accord-
ingly, density of CD8-TILs was lower in N+ adeno-
carcinomas relatively to N0, albeit not significantly 
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Fig. 2 Distribution of immune cells in duodenal cancer specimens. 
a Density (IRA%, percentage of immunoreactive area) of immune 
cells at the invasive margin (n = 18). b Correlation between density 
(IRA%) of CD45RO-TILs and  IL17+ cells at the invasive margin (n = 18; 
r = 0.61; p = 0.007 by Spearman analysis). c Correlation between 
density (IRA %) of CD8-TILs and PD1-TILs at the invasive margin 
(n = 18; r = 0.53; p = 0.023 by Spearman analysis). d Comparison 
between density (IRA%) of CD45RO-TILs and CD8-TILs in the tumor 
core (TC) and at the invasive margin (IM) (n = 18; p = ns by Mann–
Whitney). e, f Correlation between density of immune cell infiltration 
at invasive margin (IM) and tumor core (TC) of CD45RO-TILs (n = 18, 
r = 0.68; p = 0.002 by Spearman analysis) (e) and CD8-TILs (f) (n = 18, 
r = 0.64; p = 0.004 by Spearman analysis)
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(median 0.29 vs 1.07; p = 0.090 by Mann–Whitney), 
(Fig.  4a, left). Furthermore, stratifying patients for 
the N status, we observed a difference of CD8-TILs 
density among groups (p = 0.065 by Kruskall-Wallis) 
(Fig.  4a, right). The density of CD8-TILs progressively 
decreased with the increasing of the N stage, suggest-
ing that CD8-TIL infiltration may be protective against 
nodal metastatization. We also observed a correlation 
between CD45RO-TILs and LNR, albeit not significant 
(p = 0.090), while no significant correlation was found 
between density of CD45RO-TILs and nodal metastatic 
status. 
When looking at recurrence, Mann–Whitney analy-
sis evidenced a lower density of CD8-TILs in patients 
who experienced recurrence and died for the disease, 
albeit not significant (median:0.276 vs 0.524; p = 0.079) 
(Fig.  4b, left). Notably, CD68-TAM distribution was 
significantly different in patients who had recurrence 
versus patients who did not (median 1.028 vs 2.276; 
p = 0.036) (Fig.  4b, right), suggesting a protective role 
also for macrophages, in line with data on human CRC. 
As to CD45RO-TILs, their density was not associated 
to recurrence (p = 0.165).
Discussion
The aim of this study was to document density and type 
of immune cells in duodenal cancer, an extremely rare 
neoplastic condition, for which limited knowledge of 
the immune microenvironment is available. Our study 
encompassed the analysis of specific types of immune 
cells that we selected based on current literature. In par-
ticular, CD45RO+ , indicating memory T cells, CD8+ T 
cells, CD20+ B cells and CD68+ macrophages have been 
convincingly shown to associate with prognosis in the 
context of other gastrointestinal malignancies (i.e. colo-
rectal cancer and pancreatic adenocarcinoma) [20–24], 
while IL-17 (indicating Th17 T cells mostly, but also 
other myeloid types) and PD-1 identify cells with critical 
roles at mucosal sites [25–27] or in the context of immu-
notherapy [28–30] respectively.
CD45RO+ cells were the most frequent immune type, 
closely followed by CD68-TAMs, while PD-1+ T cells 
and IL-17+ cells were found at lower levels compared to 
other immune types, as expected. Besides the density of 
immune cells, we considered their localization either in 
the core or at the invasive margin of the tumor and the 
presence of scattered cells versus the organization in 
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Fig. 3 Distribution of immune populations according to 
histopathological features. a Immune cell density (IRA%) in 
DA (Duodenal Adenocarcinoma; n = 12); DA on Ad (Duodenal 
Adenocarcinoma progressed from Adenoma; n = 3) and Ad 
(Adenoma; n = 3). b Density of immune cells in duodenal cancer 
specimens according to histotype: NOS (Not Otherwise Specified; 
n = 7); MUC (Mucinous histotype; n = 5); INT (Intestinal histotype; 
n = 1); AD SQ (Adenosquamous histotype; n = 1). * p = 0.01 by Mann–
Whitney
Table 2 Spearman’s Rho correlation between  immune 
cells and lymphnode invasion
*Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.01 level (2-tailed)
LNR: Lymph node ratio. n° LN+ : number of metastatic lymph nodes
LNR n° LN+
CD45RO mean  %area
 Correlation coefficient − .452 − .369
 Sig. (2-tailed) .091 .176
CD8 mean  % area
 Correlation coefficient − .625(*) − .596(*)
 Sig. (2-tailed) .013 .019
CD20 TIL mean  %area
 Correlation coefficient − .136 − .110
 Sig. (2-tailed) .630 .697
CD20 TLT mean  %area
 Correlation coefficient − .422 − .340
 Sig. (2-tailed) .117 .215
CD68 mean  %area
 Correlation coefficient − .463 − .361
 Sig. (2-tailed) .082 .186
IL-17 mean  %area
 Correlation coefficient − .429 − .390
 Sig. (2-tailed) .110 .150
PD-1 mean  %area
 Correlation coefficient − .177 − .125
 Sig. (2-tailed) .528 .657
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lymphoid aggregates, in order to adequately capture criti-
cal features of the immune microenvironment. Accord-
ing to localization, CD45RO+ T cells and CD8+ T cells, 
the key variables considered for the Immunoscore in 
colo-rectal cancer (CRC), presented no major differ-
ence, both the populations being uniformly distributed 
at the invasive margin and in the tumor core. According 
to distribution, infiltrating CD20+ B cells were preferen-
tially localized in lymphoid aggregates, although there 
was a correlation between the density of CD20-TILs and 
CD20-TLT.
Distribution of immune cells in adenomas compared 
to duodenal cancers or duodenal cancers progressed 
from adenomas was quite homogeneous, suggesting a 
lack of modification of immune infiltrate in malignant 
and benign lesions. This could be ascribed to different 
reasons; in the first place, the presence of immune cells 
in benign lesions (adenomas) could mirror an early 
activation of the immune response in the early steps of 
tumorigenesis. At the same time, however, it should be 
pointed out that the mucosa of the small bowel hosts 
resident populations of immune cells that could inter-
fere with our analysis focused on tumor-infiltrating 
cells. Since we do not have any means to discriminate 
resident from infiltrating immune cells, this hypothesis 
remains open and only future analyses encompassing 
control specimens could help answering this question.
In human pancreatic adenocarcinoma (PDAC), den-
sity of B cells within lymphoid tissue (CD20-TLT) was 
significantly associated with longer survival [20]. A 
possible explanation, substantiated by evidence in the 
literature and gene expression signature of B cells, is 
that B cells in lymphoid tissue receive important activa-
tion signals that can be critical to mount an antitumor 
immune response. Lymphoid tissue has been associ-
ated to favourable prognosis also in colo-rectal can-
cer patients [22]. In contrast, no prognostic function 
or association with clinical features was observed for 
CD20+ B cells in duodenal cancer. This could be due 
to the fact that lymphoid tissue is a common compo-
nent of the gut-associated lymphoid tissue (GALT) and 
neoformation of lymphoid tissue, as observed in PDAC, 
does not confer a benefit during cancer progression.
A major point of our study was to assess the clinical 
relevance of immune cells in DA, by testing the rela-
tionship of immune cell infiltration with well-known 
clinical-pathological prognostic factors. We found a 
significant inverse correlation of CD8+ cell density 
with nodal involvement, suggesting that an increased 
number of these cells could protect from nodal metas-
tasis. This was further corroborated by a decreased 
CD8-TIL infiltration in patients who relapsed sug-
gesting that adaptive immune escape and particularly 
lack of cytotoxic T cell infiltration may correlate with 
a more aggressive phenotype, as is the case in CRC 
[14]. As to CD45RO, commonly used in prognostica-
tion studies, this marker was not significantly associ-
ated to clinical variables in duodenal cancer. Possible 
explanation could be that expression of this marker is 
not capable to capture specific immune subsets with a 
defined antitumor fucntion. The positive prognostic 
value of CD8-TILs may seem in contrast with the cor-
relation between CD8 and PD-1, since PD-1 is usually a 
marker of exhausted lymphocytes. However, PD-1+ T 
cells have multiple functions, far from being merely 
associated to immunosuppression [31]. More detailed 
studies are required to define the profile of T cells infil-
trating DA. There was also a significant correlation of 
CD68+ TAMs with absence of recurrence, again in line 
with studies showing a positive prognostic function 
of macrophages in human CRC [24, 32]. Interaction 
of macrophages with anticancer treatments, includ-
ing chemotherapy, has been shown to polarize their 
function towards an antitumor mode; this possibility 
remains to be tested in DA.
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Fig. 4 Correlation of immune cell density with clinical variables. a, 
left Density (IRA %) of CD8-TILs according to presence (N+ ; n = 8) 
or not (N0; n = 7) of metastatic lymphnodes (p = 0.093 by Mann–
Whitney). a, right Density (IRA %) of CD8-TILs according to N stage 
(N0: no lymph nodes, n = 7; N1: 1 metastatic lymph node, n = 2; N2, 
more than 1 metastatic lymph node, n = 6; p = 0.064 by Kruskal–
Wallis). b Density (IRA %) of CD8-TILs (left) in patients with recurrence 
(n = 3) and no recurrence (n = 9; p = 0.09 by Mann–Whitney) and 
density (IRA %) of CD68-TAMs (right) in patients with recurrence 
(n = 3) and no recurrence (n = 9; p = 0.036 by Mann–Whitney)
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Conclusions
Our analysis provides a novel characterization of immune 
infiltrate in DA. We describe how different immune sub-
sets are related to well-known clinical and pathologi-
cal characteristics of the disease, and suggest that T cell 
infiltration may play a protective role towards lymphatic 
spread of disease and nodal metastatization. Also, T cell 
density and macrophage infiltration may lower the risk 
of recurrence and disease related death. Despite the fact 
that our findings are in line with results of previous stud-
ies conducted in other malignancies including CRC and 
pancreatic cancer, a clear limitation of our study was the 
limited number of specimens determined by the low inci-
dence of the disease. A multicentric approach, allowing 
analysis of larger cohorts of patients, could circumvent 
this constraint and increase the power of our obser-
vations. It would also be useful to investigate a larger 
number of adenomas, possibly including endoscopically 
resected lesions, in order to better characterize the evolu-
tion of immune infiltrate along the process of tumorigen-
esis. Ultimate goal is including easily assessable immune 
markers in the prognostic stratification algorithm of duo-
denal cancer, to better guide post-operative treatment.
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